Jin Li

Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction

Jin Li, Shukui Qin, Jianming Xu et al. · Journal of Clinical Oncology · 2016 · 997 citations

Medicine, Oncology, Pharmacology +15

The Chinese Society of Clinical Oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer

Feng‐Hua Wang, Lin Shen, Jin Li et al. · Cancer Communications · 2019 · 856 citations · Full text

Medicine, Oncology, Gastroenterology +8

Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial

Jin Li, Shukui Qin, Rui‐Hua Xu et al. · The Lancet Oncology · 2015 · 816 citations

Medicine, Oncology, Pharmacotherapy +10

Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study

Timothy Price, Marc Peeters, Tae Won Kim et al. · The Lancet Oncology · 2014 · 470 citations · Full text

Medicine, Oncology, Pharmacology +9

Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple-negative breast cancer

Xichun Hu, Jian Zhang, Binghe Xu et al. · International Journal of Cancer · 2014 · 269 citations · Full text

Pharmacy, Oncology, Pharmacology +17